Chimeric Antigen Receptor Modified T Cells Infusion
Relapsed
Henan Cancer HospitalCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Relapsed cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
Pembrolizumab Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
Cyclophosphamide Memorial Sloan Kettering Cancer Center | Phase 2 | CCC |
cd19/cd22-bispecific car-t cells Henan Cancer Hospital | Phase 1 | CC |
cd19/cd20/bcma car-t Shanghai Cell Therapy Group Co.,Ltd | Early Phase 1 | C |
Venetoclax Institute of Hematology & Blood Diseases Hospital, China | N/A | D |
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →